Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 366

Results For "ED"

11244 News Found

Merck to showcase 100+ oncology studies at 2026 ASCO meeting
R&D | May 14, 2026

Merck to showcase 100+ oncology studies at 2026 ASCO meeting

Highlighting KEYTRUDA & expanding cancer pipeline


Wegovy delivers consistent weight loss & heart benefits for women across menopause: Novo Nordisk study
News | May 14, 2026

Wegovy delivers consistent weight loss & heart benefits for women across menopause: Novo Nordisk study

Nearly one in five women worldwide are now living with obesity


Pfizer scores landmark EU approval for  hemophilia drug HYMPAVZI
Drug Approval | May 14, 2026

Pfizer scores landmark EU approval for hemophilia drug HYMPAVZI

The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy


AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX
interviews | May 13, 2026

AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX

We are building an AI-native operating system for pharma sales and distribution


Roche wins CE mark for Alzheimer’s blood test that could transform early diagnosis
R&D | May 13, 2026

Roche wins CE mark for Alzheimer’s blood test that could transform early diagnosis

The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline


Breakthrough wearable heart failure therapy enables earlier hospital discharge: UK trial
Clinical Trials | May 13, 2026

Breakthrough wearable heart failure therapy enables earlier hospital discharge: UK trial

Researchers reported that patients treated with the wearable system were discharged around five days earlier than those receiving standard hospital-based care


Mankind’s Rajeev Juneja contributes Rs. 9.17 crore to National Defence Fund
News | May 13, 2026

Mankind’s Rajeev Juneja contributes Rs. 9.17 crore to National Defence Fund

This marks the second consecutive year that Juneja has made a personal contribution towards supporting the armed forces


Vyome secures exclusive license from Impetis for selective JAK inhibitor programs
News | May 13, 2026

Vyome secures exclusive license from Impetis for selective JAK inhibitor programs

The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments